AACR 2025 Highlights

In this episode of Lung Cancer Considered, host Dr. Stephen Liu and Dr. Christine Lovly discuss the significant lung cancer findings presented at the American Association for Cancer Research (AACR) 2025 Annual Meeting.  They discuss the results from the Beamion LUNG-1 trial, a phase 1a/1b dose escalation trial with dose confirmation and expansion, which showed that zongertinib elicited durable responses in patients with advanced, previously treated, unresectable or metastatic non-small cell lung cancer (NSCLC) that harbored a HER2 mutation, while sparing EGFR, limiting associated toxicities.

The podcast also covered the AENEAS study, a phase III trial comparing first-line aumolertinib—a third-generation EGFR tyrosine kinase inhibitor (TKI) approved in China—alone or in combination with chemotherapy for patients with EGFR-mutated NSCLC.